(46 days)
Not Found
Not Found
No
The device description explicitly states it uses visual color sandwich one step immunoassay technology, and there are no mentions of AI, ML, image processing, or training/test sets.
No.
This device is an in vitro diagnostic (IVD) test used to detect hCG for pregnancy confirmation, not to treat a medical condition.
Yes
The device detects hCG in urine to confirm pregnancy, which is a diagnostic purpose to identify a physiological condition.
No
The device description clearly indicates it is an immunoassay test kit that uses visual color sandwich one step immunoassay technology, which is a hardware-based test.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the device is intended for "clinical laboratories (labs) and physician's office labs (POLs) as an IVD test for the qualitative measurement of hCG in urine."
- Device Description: The description details an "Immunoassay for the Qualitative Detection of Human Chorionic Gonadotropin (hCG) in Urine," which is a common type of in vitro diagnostic test.
- Performance Studies: The document describes performance studies using "clinical sample correlation study" and "clinical laboratory study," which are typical evaluations for IVD devices.
- Predicate and Reference Devices: The mention of predicate and reference devices (other commercially available pregnancy tests) further confirms its classification as an IVD, as these comparisons are part of the regulatory process for IVDs.
The entire context of the document points to this device being an in vitro diagnostic intended for use in a laboratory setting to diagnose pregnancy by analyzing a biological sample (urine).
N/A
Intended Use / Indications for Use
The QuickStick ProTM HCG Test is intended to detect the presence of Human Chorionic Gonadotropin (hCG) in Urine. HCG is a well known and established analyte used to confirm pregnancy because of its early appearance in urine following conception followed by a dramatic increase in concentration. This device is intended for clinical laboratories and physician's office labs as an IVD test for the qualitative measurement of hCG in urine.
This test detects hCG in urine. hCG is a hormone produced by the placenta shortly after implantation. Since hCG is present in the urine of a pregnant woman, it is an excellent marker for confirming pregnancy. This device is intended for clinical laboratories (labs) and physician's office labs (POLs) as an IVD test for the qualitative measurement of hCG in urine. Clinical labs can include hosptials and reference labs. POLs can include mini-clinics.
Product codes (comma separated list FDA assigned to the subject device)
JHI
Device Description
The QuickStick ProTM HCG Test, like many commercially available pregnancy test kits, qualitatively measures the presence of HCG by visual color sandwich one step immunoassay technology.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
clinical laboratories and physician's office labs
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The product performance characteristics of the QuickStick ProTM HCG Pregnancy Test were evaluated in a clinical sample correlation study and a blind labeled spiked HCG study. The results of these studies demonstrate the Phamatech QuickStick Pro™ HCG Test to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of early pregnancy. Correlations studies, using clinical specimens, produced a >99% correlation when compared to the Quidel Rapidvue (San Diego, CA 92121) and the Syntron Bioresearch Be Sure Pregnancy Test (Vista, CA 92083). A clinical laboratory study was performed, the Phamatech QuickStick ProTM exhibited excellent sensitivity (>99%), specificity (>99%), and accuracy (>99%) in the hands of professional users.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity (>99%), specificity (>99%), and accuracy (>99%)
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1155 Human chorionic gonadotropin (HCG) test system.
(a)
Human chorionic gonadotropin (HCG) test system intended for the early detection of pregnancy —(1)Identification. A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class II.(b)
Human chorionic gonadotropin (HCG) test system intended for any uses other than early detection of pregnancy —(1)Identification. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class III.(3)
Date PMA or notice of completion of a PDP is required. As of the enactment date of the amendments, May 28, 1976, an approval under section 515 of the act is required before the device described in paragraph (b)(1) may be commercially distributed. See § 862.3.
0
JAN 26 1998
510 (k) SUMMARY AS REQUIRED BY SECTION 807.92(C)
QuickStick ProTM HCG Test (9009) ldentification:
Immunoassay for the Qualitative Detection of Human Chorionic Description: Gonadotropin (hCG) in Urine for the Early Pregnancy
Name Of Manufacturer:
Phamatech 9265 Activity Road #112 San Diego, California 92126, USA
Intended Use: The QuickStick ProTM HCG Test is intended to detect the presence of Human Chorionic Gonadotropin (hCG) in Urine. HCG is a well known and established analyte used to confirm pregnancy because of its early appearance in urine following conception followed by a dramatic increase in concentration. This device is intended for clinical laboratories and physician's office labs as an IVD test for the qualitative measurement of hCG in urine.
The QuickStick ProTM HCG Test, like many commercially available Technology: pregnancy test kits, qualitatively measures the presence of HCG by visual color sandwich one step immunoassay technology. Examples of such predicate devices include the Unipath Clearview HCG (Mountainview, CA 94043), Abbott Laboratories' Fact Plus (Abbott Park, IL 60064) and the Syntron Bioresearch Be Sure Pregnancy Test (Vista, CA 92083). All of the above devices rely on the basic immunochemical sandwich assay principle of recognition and formation of specific antibody / HCG / antibody / complexes.
Performance: The product performance characteristics of the QuickStick ProTM HCG Pregnancy Test were evaluated in a clinical sample correlation study and a blind labeled spiked HCG study. The results of these studies demonstrate the Phamatech QuickStick Pro™ HCG Test to be substantially equivalent to the reported performance characteristics of other commercially available tests for the qualitative detection of early pregnancy. Correlations studies, using clinical specimens, produced a >99% correlation when compared to the Quidel Rapidvue (San Diego, CA 92121) and the Syntron Bioresearch Be Sure Pregnancy Test (Vista, CA 92083). A clinical laboratory study was performed, the Phamatech QuickStick ProTM exhibited excellent sensitivity (>99%), specificity (>99%), and accuracy (>99%) in the hands of professional users.
Conclusion: For the reasons mentioned above, it may be concluded that the Phamatech QuickStick ProTM HCG Test is substantially equivalent to a variety of pregnancy tests currently in commercial distribution.
1
Image /page/1/Picture/1 description: The image shows the logo for the Department of Health & Human Services (HHS) in the USA. The logo features a stylized eagle with three stripes forming its wing, symbolizing strength and protection. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged around the eagle, indicating the department's name and country.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
JAN 26 1998
Carl Mongiovi Director of Operations Phamatech 9265 Activity Road #112-113 San Dieqo, California 92126
Re : K974615 QuickStick Pro™ HCG Test Regulatory Class: II Product Code: JHI Dated: December 10, 1997 Received: December 11, 1997
Dear Mr. Mongiovi:
regulations.
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. ದ substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in requlatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or
2
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact. the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Bitman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
INDICATIONS FOR USE
Applicant: Phamatech
510(k) Number (if known): _
Device Name: QuickStick Pro IM Pregnancy Test
Indications for Use:
This test detects hCG in urine. hCG is a hormone produced by the placenta shortly after implantation. Since hCG is present in the urine of a pregnant woman, it is an excellent marker for confirming pregnancy. This device is intended for clinical laboratories (labs) and physician's office labs (POLs) as an IVD test for the qualitative measurement of hCG in urine. Clinical labs can include hosptials and reference labs. POLs can include mini-clinics.
PLEASE DO NOT WRITE BELOW THIS LINE
Concurrence of CDRH Office of Device Evaluation (ODE)
Division Sign-Off Division of Clinical Laboratory Devices 510(k) Number:
Prescription Use:
Per 21 CFR 801.109
OR Over the Counter -
Kmoore for Montgomery
(Division Sign-Off)
11
Division of Clinical Laboratory Devices
510(k) Number 974615